Haemonetics (NYSE:HAE) announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.18, Briefing.com reports. Haemonetics had a return on equity of 21.07% and a net margin of 5.05%. The business had revenue of $238.50 million during the quarter, compared to analysts’ expectations of $236.82 million. During the same period in the previous year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. Haemonetics updated its FY 2020 guidance to $2.95-3.15 EPS and its FY20 guidance to $2.95-3.15 EPS.
NYSE:HAE opened at $136.10 on Friday. Haemonetics has a 1 year low of $80.24 and a 1 year high of $137.49. The company has a current ratio of 2.10, a quick ratio of 1.34 and a debt-to-equity ratio of 0.54. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of 56.95, a PEG ratio of 3.36 and a beta of 0.82. The stock has a 50-day moving average price of $124.08 and a two-hundred day moving average price of $101.19.
In other news, VP Dan Goldstein sold 475 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $133.23, for a total value of $63,284.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ronald G. Gelbman sold 1,696 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $134.15, for a total value of $227,518.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,830 shares of company stock valued at $5,153,165. Insiders own 1.32% of the company’s stock.
A number of brokerages recently commented on HAE. JMP Securities lifted their price objective on Haemonetics to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. Morgan Stanley lifted their price objective on Haemonetics from $128.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Raymond James lifted their price objective on Haemonetics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. Jefferies Financial Group lifted their price objective on Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Finally, Barrington Research reaffirmed an “outperform” rating and set a $139.00 price objective (up from $116.00) on shares of Haemonetics in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $140.67.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Read More: What is a death cross?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.